A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease
Latest Information Update: 25 Apr 2024
At a glance
- Drugs Ninerafaxstat (Primary)
- Indications Angina pectoris; Myocardial ischaemia
- Focus Adverse reactions; Proof of concept
- Acronyms IMPROVE-Ischemia
- Sponsors Imbria Pharmaceuticals
- 22 Apr 2024 Status changed from active, no longer recruiting to completed.
- 13 Mar 2024 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 19 Jan 2024 This trial has been completed in Denmark, according to European Clinical Trials Database record.